| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1223877 | Journal of Pharmaceutical and Biomedical Analysis | 2008 | 5 Pages |
Abstract
One unknown impurity (degradation product) present at a level below 0.1% in the initial samples increased to a level of 0.5% in 6 M/40 °C/75% RH stability samples of risperidone tablets was detected by gradient reverse-phase high-performance liquid chromatography (HPLC). This impurity was isolated using reverse-phase preparative liquid chromatography. Based on the spectral data the structure of this impurity is characterized as 3-[2-[4-[6-fluoro-1,3-benzoxazol-2-yl]piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a] pyrimidin-4-one. Structural elucidation of this impurity by spectral data (1H NMR, 13C NMR, DEPT, MS and IR), formation and mechanism has been discussed in detail.
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Ch. Bharathi, D. Krishnama Chary, M. Saravana Kumar, Rama Shankar, V.K. Handa, Ramesh Dandala, A. Naidu,